Oxford MESTAR Ltd, in collaboration with an interdisciplinary UCL team from Division of Surgery & Interventional Science and partners in China (Tsinghua University and Shenzhen Lando Co. Ltd), has been awarded a £2m Innovate UK-MoST grant to develop novel osteochondral scaffold technology as a treatment for early intervention of osteoarthritis. Osteochondral scaffold technology is […]
PRESS RELEASE Oxford MEStar announces non-binding letter of intent with Elanix Biotechnologies in regard to setting up a JV to market GynRepair in China Oxford, 22 November, 2016 Oxford MEStar Ltd (“MEStar”), an Oxford University spin-out, today announced that the company has entered into a non-binding letter of intent (LOI) with Elanix Biotechnologies AG. The […]
Oxford MEStar Ltd (“MEStar”), an Oxford University spin-out, has acquired selected intellectual property, trademarks and assets from Mode Diagnostics Ltd (“Mode”) for an undisclosed sum. Professor Zhanfeng Cui, the founder of MEStar, commented: “We are excited about the long term commercial potential of using this technology. We believe the IP developed by Mode, a proprietary […]
Oxford MEStar Ltd, a rapidly growing company specialising in translational and regenerative medicine, announces that it is part of a consortium that has been awarded an Arthritis Research UK (ARUK) Point of Care grant to develop novel functionally man-made osteochondral scaffold for large osteochondral defect repairs. Osteochondral injury refers to repetitive trauma within a joint […]
